LinkedIn
WebsiteIntroduction
Silo Pharma Inc. (Nasdaq: SILO) is a developmental-stage biopharmaceutical company based in Englewood Cliffs, New Jersey. The firm focuses on developing formulations of traditional and psychedelic therapeutics to address conditions such as post-traumatic stress disorder (PTSD), stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Through licensing agreements and acquisitions of proprietary technology from academic institutions, Silo Pharma utilizes the 505(b)(2) regulatory pathway to aim for reduced development costs and expedited entry to market.
Corporate Structure and Team
As of September 2025, Silo Pharma employs between 11 and 50 individuals. Leadership comprises Eric Weisblum (Chief Executive Officer), Dr. James Kuo (Vice President of R&D), Daniel Ryweck (Chief Financial Officer), and board members Dr. Kevin Muñoz and Wayne Linsley. Wayne Linsley worked at a financial reporting firm specializing in SEC filings from 2009 until September 2021 and currently serves on two additional public company boards. Scientific guidance is provided by Dr. Josh Woolley, MD/PhD.
PTSD treatment by Rosa Rafael
Recent Developments and News
In 2025, Silo Pharma announced several developments in its pipeline:
• A partnership with Resyca to study a microchip-based nasal spray delivery system for SPC-15, an intranasal prophylactic treatment for PTSD.
• Selection of Veloxity Labs, LLC for bioanalytical IND-enabling studies for SPC-15.
• Initiation of a safety study at Frontage Laboratories, Inc., moving SPC-15 toward first-in-human trials pending FDA guidance on the pre-IND submission.
• Announcement of preclinical results for SP-26, an extended-release ketamine implant intended for fibromyalgia, meeting specified preclinical endpoints.
Financial and Strategic Analysis
On September 23, 2025, SILO shares closed at USD 1.10, reflecting a 40.41% increase in intraday trading volume, with 9,171,267 shares traded on the Nasdaq exchange. This change is associated with investor interest in the company's forthcoming clinical milestones. Silo Pharma’s focus on the 505(b)(2) pathway is designed to reduce capital requirements and shorten development timelines by building on existing safety and efficacy data. Licensing agreements with research partners provide a portfolio of patent-protected assets.
Market Position and Industry Context
The central nervous system therapeutics market is projected to grow at a compound annual growth rate of 10.5%, increasing from USD 155.5 billion in 2025 to USD 381.3 billion by 2034. No new drug for PTSD has been approved in nearly 25 years, addressing an unmet need impacting approximately 3.9% of the global population. Silo Pharma’s pipeline, including SPC-15 for PTSD, SP-26 for fibromyalgia, and additional assets targeting Alzheimer’s disease and stress-induced psychiatric disorders, places it within a sector focused on underserved indications.
tl;dr
SILO shares increased 40.41% to USD 1.10 on September 23, 2025, as Silo Pharma progresses its lead PTSD asset SPC-15 through IND-enabling studies with Resyca, Veloxity Labs, and Frontage Laboratories. Preclinical results with SP-26 demonstrate potential for fibromyalgia treatment, while the 505(b)(2) regulatory strategy positions the company for potential first-in-human trials in the near future.
